Vanguard Personalized Indexing Management LLC Acquires 1,067 Shares of Envista Holdings Corporation $NVST

Vanguard Personalized Indexing Management LLC increased its holdings in Envista Holdings Corporation (NYSE:NVST) by 5.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,100 shares of the company’s stock after buying an additional 1,067 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Envista were worth $393,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Parallel Advisors LLC raised its position in Envista by 100.1% in the second quarter. Parallel Advisors LLC now owns 2,792 shares of the company’s stock worth $55,000 after acquiring an additional 1,397 shares during the period. FourThought Financial Partners LLC purchased a new stake in shares of Envista in the 1st quarter worth $180,000. Vestcor Inc bought a new position in Envista in the 1st quarter worth $211,000. Aigen Investment Management LP purchased a new position in Envista during the first quarter valued at $274,000. Finally, State of Wyoming grew its holdings in Envista by 121.1% during the first quarter. State of Wyoming now owns 16,911 shares of the company’s stock valued at $292,000 after purchasing an additional 9,264 shares during the period.

Wall Street Analysts Forecast Growth

NVST has been the subject of a number of analyst reports. Evercore ISI set a $25.00 price target on Envista in a research report on Wednesday, October 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of Envista in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Envista from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 30th. Mizuho lifted their price target on shares of Envista from $15.00 to $18.00 and gave the company an “underperform” rating in a report on Friday, August 1st. Finally, Stifel Nicolaus upped their price target on shares of Envista from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Envista has an average rating of “Hold” and a consensus target price of $21.08.

Envista Stock Up 2.0%

Shares of NVST stock opened at $20.24 on Friday. The company’s fifty day simple moving average is $20.59 and its two-hundred day simple moving average is $19.15. Envista Holdings Corporation has a 52 week low of $14.22 and a 52 week high of $23.00. The stock has a market cap of $3.36 billion, a P/E ratio of 63.25, a PEG ratio of 1.07 and a beta of 1.01. The company has a quick ratio of 2.08, a current ratio of 2.44 and a debt-to-equity ratio of 0.46.

Envista (NYSE:NVST) last issued its earnings results on Thursday, July 31st. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.02. The firm had revenue of $682.10 million for the quarter, compared to analysts’ expectations of $638.21 million. Envista had a return on equity of 4.84% and a net margin of 2.11%.The business’s revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.11 earnings per share. Envista has set its FY 2025 guidance at 1.050-1.15 EPS. Analysts predict that Envista Holdings Corporation will post 1 EPS for the current fiscal year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.